Iatrogenic botulism after botulinum toxin type A injections

Area of Science:

• Neurology
• Toxicology
• Pharmacology

Background:

• Botulinum toxin type A (BT/A) is widely used for therapeutic applications, including treating spasticity and blepharospasm.
• While generally safe, BT/A can rarely cause iatrogenic botulism, a serious condition characterized by generalized weakness, dysphagia, and respiratory distress.

Observation:

• This study reports on four patients who developed iatrogenic botulism after receiving therapeutic doses of BT/A.
• One patient required intensive care unit admission, but all patients experienced a full recovery.

Findings:

• The adverse effect of iatrogenic botulism following therapeutic BT/A administration is a rare but significant complication.
• Hematological spread of the toxin is the most probable cause of BT/A-induced botulism.

Implications:

• Understanding the potential for toxin spread is crucial for managing BT/A therapy risks.
• This highlights the importance of vigilant patient monitoring for rare adverse events.
• Further research into the mechanisms of BT/A spread may inform safer therapeutic strategies.